Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2471-2475

  Naito, Y ^a,b   Kubota, K ^b,c   Ohmatsu, H ^b   Goto, K ^b   Niho, S ^b   Yoh, K ^b   Ohe, Y ^b  

^a TORANOMON HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Docetaxel; Nedaplatin; Non small cell lung cancer; Squamous cell carcinoma

Indexed keywords

DOCETAXEL; NEDAPLATIN;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GRANULOCYTE; HUMAN; LEUKOCYTE; LUNG SQUAMOUS CELL CARCINOMA; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; VOMITING;

EID: 80155174224     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq781     Document Type: Article

References (41)

1. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-299.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Kelly K, Crowley J, Bunn PA Jr. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
4. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
5. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617-4625.
6. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
7. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
8. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311.
9. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
10. Morita S, Okamoto I, Kobayashi K et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15: 4493-4498.
11. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
12. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
13. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
14. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
15. Kubota K, Masuhara H, Hosoya K et al. Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18S): (Abstr 7114).
16. Furuse K, Fukuoka M, Kurita Y et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho 1992; 19: 879-884.
17. Fukuda M, Shinkai T, Eguchi K et al. Phase II study of (glycolate-O, O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990; 26: 393-396.
18. Naito Y, Kubota K, Ohmatsu H et al. Phase I/II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Nihon Kokyuki Gakkai Zassi 2009; 47: 270 (Abstr PP682).
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
20. Furuse K, Fukuoka M, Asamoto H et al. A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Gan To Kagaku Ryoho 1992; 19: 1019-1026.
21. Hirose T, Horichi N, Ohmori T et al. Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced nonsmall cell lung cancer. Lung Cancer 2003; 39: 91-97.
22. Kurata T, Tamura K, Yamamoto N et al. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 2004; 90: 2092-2096.
23. Shirai T, Hirose T, Noda M et al. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer 2006; 52: 181-187.
24. Oshita F, Yamada K, Kato Y et al. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 52: 73-78.
25. Oshita F, Yamada K, Saito H et al. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J Exp Ther Oncol 2004; 4: 343-348.
26. Yoshiike F, Koizumi T, Kitaguchi Y et al. Phase I trial of nedaplatin and paclitaxel for patients with non-small cell lung cancer. J Chemother 2005; 17: 550-554.
27. Okuda K, Hirose T, Ishida H et al. Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2008; 61: 829-835.
28. Hirose T, Sugiyama T, Kusumoto S et al. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Anticancer Res 2009; 29: 1733-1738.
29. Osaka Y, Takagi Y, Hoshino S et al. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus 2006; 19: 473-476.
30. Yoshioka T, Sakayori M, Kato S et al. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 2006; 11: 454-460.
31. Nakajima Y, Suzuki T, Haruki S et al. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer. Hepatogastroenterology 2008; 55: 1631-1635.
32. Jin J, Xu X, Wang F et al. Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/ recurrent esophageal squamous cell carcinoma. J Thorac Oncol 2009; 4: 1017-1021.
33. Miyazaki A, Kobayashi J, Yamamoto T et al. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma. Oral Oncol 2008; 44: 471-476.
34. Nakajima O, Inoue S, Kobayashi K. Differences in intracellular uptake of cisplatin, carboplatin and 254-S among human lung cancer cell lines. Japan J Lung Cancer 1994; 34: 313-319.
35. Sekine I, Nokihara H, Horiike A et al. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Br J Cancer 2004; 90: 1125-1128.
36. Grossi F, Aita M, Defferrari C et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009; 14: 497-510.
37. Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22: 254-261.
38. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
39. Taxotere(R) the Japanese Package Insert
40. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
41. Koukourakis MI, Kapsoritakis A, Maltezos E et al. Unexpected toxicity after low-dose docetaxel treatment of a cancer patient with clinically latent HCV-positive hepatic cirrhosis. Anticancer Res 2002; 22: 2491-2492.